|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0221908,
umls-concept:C0280100,
umls-concept:C0348016,
umls-concept:C0439659,
umls-concept:C0442027,
umls-concept:C0524527,
umls-concept:C1135135,
umls-concept:C1135136,
umls-concept:C1135137,
umls-concept:C1706947
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-4-14
|
|
pubmed:abstractText |
An intravenous (IV) erlotinib formulation has not been characterized in cancer patients but may be useful in those with gastrointestinal abnormalities that impact on the ability to take oral medication. This study sought to determine the maximum tolerated dose (MTD) of erlotinib administered as a single 30-min infusion in patients with advanced solid tumors and absolute bioavailability of erlotinib tablets at matched doses.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
53-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19956953-Administration, Oral,
pubmed-meshheading:19956953-Adolescent,
pubmed-meshheading:19956953-Adult,
pubmed-meshheading:19956953-Aged,
pubmed-meshheading:19956953-Biological Availability,
pubmed-meshheading:19956953-Dose-Response Relationship, Drug,
pubmed-meshheading:19956953-Drug Administration Schedule,
pubmed-meshheading:19956953-Female,
pubmed-meshheading:19956953-Humans,
pubmed-meshheading:19956953-Infusions, Intravenous,
pubmed-meshheading:19956953-Male,
pubmed-meshheading:19956953-Maximum Tolerated Dose,
pubmed-meshheading:19956953-Middle Aged,
pubmed-meshheading:19956953-Neoplasm Metastasis,
pubmed-meshheading:19956953-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:19956953-Protein Kinase Inhibitors,
pubmed-meshheading:19956953-Quinazolines
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
|
|
pubmed:affiliation |
Department of Medical Oncology, University of Manchester, Christie Hospital NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. malcolm.ranson@manchester.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
